Sanofi: Lixisenatide moves one step forward in the US

BUY, Fair Value EUR80 (+11%)

News published on February Tuesday 19, 2013
Share on

Sanofi announced this morning that NDA for lixisenatide was accepted by the FDA for review which should translate into an action date sometime in October 2013. The NDA was based on the GetGoal programme which included 11 trials and more than 5 000 patients suffering from type II diabetes most of which uncontrolled despite different treatment lines including basal insulin. The filing also included some data from the cardiovascular outcome study ELIXA that was required by the US agency. This acceptance of filing should not come as a big surprise however.

Full report available to subscribers
Please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities